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Isoleucylcysteine dipeptide, a first intermediate peptide in bacitracin biosynthesis, was liberated from the 
enzyme protein and oxidized with manganese dioxide in dimethylsulfoxide. The resulting oxidation product 
was identified by thin-layer chromatography as 2-(2-methyl-1-oxobutyl)-thiazole-4-carboxylic acid which 
has been isolated from the hydrolysate of bacitracin F. This result shows that the intermediate dipeptide 
contains a thiazoline ring, and that the thiazoline ring is synthesized at the dipeptide stage in the process 
of peptide chain elongation in bacitracin biosynthesis. Improbability of non-enzymatic dehydrative cycliza- 
tion of the dipeptide isdiscussed. 
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1. INTRODUCTION 
Thiazoline and thiazole rings are found in 
several antibiotic polypeptides and have been 
thought to be synthesized by a dehydrative cycliza- 
tion of cysteine-containing peptides [ 11. However, 
the mechanism of biosynthesis of thiazoline ring 
has remained unsolved. 
Bacitracin A, an antibiotic polypeptide pro- 
duced by strains of Bacillus licheniformis, contains 
a thiazoline ring in the N-terminal portion of the 
molecule. One of the problems to be solved is when 
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is the thiazoline ring formed in the process of pep- 
tide elongation in bacitracin biosynthesis. In our 
previous paper [2], it was suggested that the 
enzyme-bound isoleucylcysteine dipeptide, the first 
intermediate peptide in bacitracin biosynthesis [3], 
contains a thiazoline ring. The evidence for this 
came from the finding that the dipeptide attaches 
to a thiopropyl-Sepharose 6B gel by thiol-disulfide 
exchange, only when the dipeptide is treated with 
0.5 N HCl at 60°C to open the ring structure and 
to liberate a free thiol group. In this paper, we pre- 
sent more direct evidence for the presence of a 
thiazoline ring in the dipeptide. 
2. MATERIALS AND METHODS 
2.1. Chemicals 
The sources of materials used in this work were 
as follows: bacitracin (68.4 U/mg) from Sigma, L- 
[U-14C]cysteine (spec. act. 295 Ci/mol) from 
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NEN, and manganese dioxide from Junsei, used 
without any treatment for activation. 
2.2. Preparation of bacitracin synthetase 
Bacitracin synthetase was partially purified as 
described [4], and the Sephadex G-200 fraction 
was used throughout the work. 
2.3. Preparation of the “4C-labeled dipeptide’ 
The isoleucylcysteine dipeptide was prepared as 
described [2]. Briefly, the reaction mixture con- 
tained ATP, MgC12, L-isoleucine, L-[r4C]cysteine, 
dithiothreitol and the enzyme fraction. After in- 
cubation at 37°C for 20 min, protein was 
precipitated with 5% trichloroacetic acid, collected 
on a glass fiber filter, and washed with 5% 
trichloroacetic acid. The precipitate was dissolved 
in 0.01 N KOH and incubated at 50°C for 30 min 
to liberate the thioester-linked dipeptide. After 
removing protein by methanol precipitation, the 
supernatant was dried and used as the 14C-labeled 
dipeptide. 
Since the isoleucylcysteine dipeptide synthesized 
by the enzyme reaction is not simple L-Be-L-Cys 
and has a ring structure as shown below, this com- 
pound will be referred to as the dipeptide or the 
i4C-labeled dipeptide throughout this paper for the 
sake of simplicity. 
2.4. Opening the thiazoline ring by acid hydrolysis 
Peptides were treated in 0.5 N HCl at 100°C for 
10 min or 60°C for 100 min to open the thiazoline 
ring, and then neutralized with 0.5 N KOH [2]. 
2.5. Conversion of a cysteine-containing peptide 
to the disulfide compound by air oxidation 
To an aqueous solution of a cysteine-containing 
peptide (less than 1 pmol), NH40H and cupric 
sulfate were added to give final concentrations of 
0.1 N and 0.01 mM, respectively. After standing 
at 37°C for 40 min, the solution was evaporated to 
dryness in vacua. 
2.4. Preparation of bacitracin Ffrom bacitracin A 
Bacitracin F was prepared by oxidation of 
bacitracin A with manganese dioxide (MnO2) by a 
modification of the method of Barton et al. [5,6]. 
Bacitracin A is the main component of commercial 
bacitracin. MnOz (6 g) was added to a solution of 
bacitracin (600 mg) in dimethylsulfoxide (DMSO, 
320 
1.5 ml). The mixture was stirred for 3 days at room 
temperature. The course of the oxidation was 
monitored by the increase in absorption maximum 
at 290 nm due to the thiazole ring of bacitracin F. 
The supernatant obtained from the mixture by cen- 
trifugation at 8000 x g for 20 min was diluted 
3-fold with water, and applied to an Amberlite 
CG-50 (H+ form) column (1.3 x 10 cm). After 
washing the column with water, bacitracin F was 
eluted with 1 N HCl containing 50% methanol. 
The eluate was evaporated to dryness. 
2.7. Preparation of 2-(2-methyl-l-oxobutyl)- 
thiazole-4-carboxylic acid (I) from 
bacitracin F 
This compound was prepared according to 
Weisiger et al. [7]. Bacitracin F was hydrolyzed at 
110°C for 18 h with 6 N HCI in a sealed tube. The 
hydrolysate was extracted three times with ethyl 
ether. The ether extract was concentrated and the 
product was crystallized from ethyl ether/petro- 
leum ether. Yield: 10%; m.p. 94-95°C. Reported 
values: 94-95°C [7], 89.5-90°C [8]. Analysis 
calculated for C9H1i03NS: C, 50.7; H, 5.22; 
N, 6.57; S, 15.0. Found: C, 50.1; H, 5.10; N, 6.57; 
s, 15.1. 
2.8. Oxidation of the dipeptide with manganese 
dioxide 
To the solution (0.5 ml) containing the 14C- 
labeled dipeptide, 0.7 pmol of compound I and 
0.35 prnol of bacitracin were added as carriers. 
The solution was evaporated to dryness in vacua, 
and 3 mg of MnOz and 0.5 ml of DMSO were add- 
ed to the residue. The mixture was shaken at 30°C 
for 4 days, diluted to 4 ml with water, and applied 
to a QAE-Sephadex (OH- form) column (1 x 
5 cm). After washing the column with water, the 
peptide was eluted with 1 N HCI. The eluate was 
extracted with ethyl ether. The ether layer was con- 
centrated in vacua. Aliquot samples were used for 
counting and the remainder was used for thin-layer 
chromatography. 
2.9. Thin-layer chromatography 
Thin-layer chromatography (TLC) was per- 
formed on Merck silica gel 60 plates (20 x 20 cm) 
with the following solvent system: (a) n-butanol/ 
acetic acid/water (4: 1 : 2, by vol.) and (b) chloro- 
form/methanol/17% NH40H (16: 15:5, by vol.). 
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Amino acids and peptides were detected with 
ninhydrin. Compound I was detected by UV ab- 
sorption. Radioactivity was scanned by a 
chromatogram scanner. 
2.10. Synthesis of L-Ile-L-Cys 
L-Ile-L-Cys was synthesized according to Stoffel 
and Craig [9], crystallized as a free state from a 
1 N HCl solution by adjusting the pH to about 4.8 
with cont. NHdOH, and recrystallized from 
water/ethanol. 
3. RESULTS 
3.1. Analysis of the 14C-labeled ipeptide by TLC 
To characterize the dipeptide, it was analysed by 
TLC. As shown in fig. 1, a radioactive peak was 
detected near the area of L-isoleucine, but it did 
not coincide in position with either L-Ile-L-Cys or 
its air-oxidized product di-L-isoleucyl-L-cystine. 
On the other hand, when the dipeptide was treated 
with 0.5 N HCl at 60°C for 100 min, air-oxidized 
and subjected to TLC, a radioactive peak cor- 
responding to di-L-isoleucyl L-cystine was ob- 
served (fig.2). These results show that the 
dipeptide is not simple L-Ile-L-Cys and can be con- 
verted to L-Ile-L-Cys by the ring-opening treat- 
ment with 0.5 N HCl, suggesting that the dipeptide 
contains a thiazoline ring. 
3.2. Identification of the dipeptide oxidized with 
MnO2 as compound I 
The results described in [2] and the previous sec- 
tion clearly show that the thiol group of the cys- 
teine residue in the dipeptide is not in a free state. 
However, this does not necessarily mean that a 
thiazoline ring is present in the dipeptide, because 
the thiol group may be blocked by some group (X 
group in fig.3) which can be removed by the ring- 
opening treatment. Therefore, to confirm more 
directly the presence of a thiazoline ring in the 
dipeptide, we tried to convert the dipeptide to a 
known compound of ring structure. If the dipep- 
tide contains a thiazoline ring, a more stable 
thiazole derivative will be formed by oxidation 
with MnOz [5]. It might be expected that this 
thiazole derivative would be identical with com- 
pound I. This idea is schematically shown in fig.3. 
As shown below, this proved to be the case. 
The 14C-labeled dipeptide was oxidized with 
-w -w 
+ He t Cys (KS+ 
L-lie-L-Cys 
(L-lie-L-bys)* 
Fig. 1. Thin-layer chromatography of the 14C-labeled 
dipeptide. Solvent system, a; 0, origin; F, solvent front. 
MnO2 in DMSO, applied to a QAE-Sephadex col- 
umn, and eluted with 1 N HCl. The eluate was ex- 
tracted with ethyl ether. 40-60’70 radioactivity 
used was recovered in the ether layer. The relative- 
ly low recovery of radioactivity in the ether layer 
would be due to the absence of a carrier having an 
identical structure. Solubility of the reaction 
product in the ether layer would be attributed to its 
aromatic ring structure. A sample of the ether 
layer was analysed by TLC. A radioactive peak 
coincided in position with compound I in the two 
solvent systems (fig.4). 
These results show that the thiazole derivative 
derived from the dipeptide is identical to com- 
pound I. Therefore, the dipeptide liberated from 
the enzyme protein by mild alkali hydrolysis cer- 
> .- 
0 
f 
(L-lle-L-iIys)2 
Fig.2. Thin-layer chromatography of the ‘%-labeled 
dipeptide which was treated with 0.5 N HCI and air- 
oxidized. Solvent system, a. 
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1 “C-Labeled dipeptide 
j Mn02 ~ 
DMSO 
Z-(Z-Methyl-loxobutyl)thiazole- 
4-carboxylic acid 
Compound I 
MnOz 
DMSO > 
Bacitracin A 
R = (CH,)(C+,)CH- 
Bacitracin F 
Fig.3. Scheme for identification of the 14C-labeled 
dipeptide oxidized with MnOz as compound I.
Gxnpo~l 
t 
lie 
L-lie-L-Cys 
B 
Fig.4. Thin-layer chromatography of the 14C-labeled 
dipeptide which was oxidized with Mn9 and extracted 
in the ether layer. (A) Solvent system a; (B) solvent 
system b. 
tainly contains a thiazoline ring and its structure is 
probably 2-(l-amino-2-methylbutyl)-4,5-dihydro- 
thiazole-4-carboxylic acid. Consequently, the ring 
structure must be formed at the dipeptide stage in 
the process of peptide elongation in bacitracin 
biosynthesis. 
4. DISCUSSION 
The results described above show that the in- 
termediate dipeptide has a structure formed by a 
cyclic condensation of L-Ile-L-Cys. The following 
properties (Ishihara, H., unpublished) of the 
dipeptide also support this assumed structure hav- 
ing one amino and one carboxyl group. (i) It was 
bound to both Dowex 50 (H+ form) and Dowex 1 
(OH- form). (ii) It migrated to the same position 
as neutral amino acids on paper electrophoresis at 
pH 6.8. 
As discussed in our previous paper [2], it has 
been reported that cysteine-containing peptide 
could be non-enzymatically cyclized to a thiazoline 
ring, only when the a-amino group of the N- 
terminal amino acid adjacent to the cysteine 
residue had been protected [9,10]. Therefore, it is 
very unlikely that thiazoline ring formation in the 
dipeptide is non-enzymatic, and that ring closure 
occurred during the course of preparation of the 
dipeptide. To confirm this, L-Ile-L-Cys (0.5 mM) 
or 0.5 N HCl-treated bacitracin (thiazoline ring be- 
ing opened, 0.18 mM), as a model compound, was 
left under the following conditions and ultraviolet 
absorption spectra were measured: (i) in 5% 
trichloroacetic acid at 4°C for 80 min; (ii) in 
0.01 N KOH at room temperature for 60 min, then 
at 50°C for 40 min; (iii) in 95% methanol at room 
temperature for 12 h; and (iv) in DMSO at 30°C 
for 3 days. As expected, no change in spectra was 
observed under these conditions. 
In preliminary experiments, we tried to separate 
the reaction of peptide bond formation from that 
of cyclization. The enzyme was treated with the 
following reagents for protein modification or 
under conditions giving 50-80% inhibition of the 
synthesis of enzyme-bound [r4C]cysteine-labeled 
dipeptide. Then the enzyme-bound product was 
liberated and assayed by TLC. These reagents and 
conditions were diethylpyrocarbonate, phenyl- 
oxazole, 2,3-butanedione, formaldehyde and 
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temperature, and acidic and alkaline pH values. In 
all cases analysed, only a radioactive peak cor- 
responding to the dipeptide having a thiazoline 
ring was detected and no radioactive peak cor- 
responding to L-Ile-L-Cys was observed. In some 
cases an additional peak corresponding to cysteine 
was detected. From these results, it seems likely 
that the two reactions are closely coupled and pro- 
ceed at the same active site. 
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